Baseline Ang-2 Serum Levels as a Predictive Factor for Survival in NSCLC and SCLC
Author:
Nikolakopoulou Asimina, Tsakogiannis DimitrisORCID, Zagouri Flora, Zografos EleniORCID, Tzioga Lamprini, Stratakos GrigoriosORCID, Koulouris NikolaosORCID, Syrigos Konstantinos, Bletsa Garyfalia
Abstract
Angiopoietin-2 (Ang-2) has been implicated in the development of several types of cancer, including lung malignancy. In the present study, we examined the impact of Ang-2 serum concentration on the development, dissemination, and 5-year overall survival of NSCLC and SCLC. A total of 99 patients with lung cancer were tested. The OS of NSCLC and SCLC patients was estimated using Kaplan–Meier curves and compared through log-rank test. The median serum level of Ang-2 at baseline in both NSCLC and SCLC patients was significantly higher than that of controls (p < 0.0001). The Ang-2 serum concentration was not related to metastasis, neither in NSCLC nor in SCLC cases. The OS was found to be significantly shorter for stage IIIβ NSCLC patients with a high baseline Ang-2 serum concentration (p = 0.012), while Cox regression analysis showed that Ang-2 is a significant independent factor for poor prognosis for stage IIIβ NSCLC (hazard ratio = 2.97, 95% CI: 1.05–8.40, p = 0.04). The concentration of Ang-2 has no impact on the prognosis of SCLC. Ang-2 could be considered as a significant molecular marker that enables the prediction of NSCLC and SCLC development, and is involved in the poor prognosis of stage IIIβ NSCLC.
Subject
Paleontology,Space and Planetary Science,General Biochemistry, Genetics and Molecular Biology,Ecology, Evolution, Behavior and Systematics
Reference45 articles.
1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA Cancer J. Clin.,2018 2. Global Burden of Disease Cancer Collaboration, Fitzmaurice, C., Dicker, D., Pain, A., Hamavid, H., Moradi-Lakeh, M., MacIntyre, M.F., Allen, C., Hansen, G., and Woodbrook, R. (2015). The Global Burden of Cancer 2013. JAMA Oncol., 1, 505–527. 3. Lung Cancer Statistics;Torre;Adv. Exp. Med. Biol.,2016 4. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: Analysis of the surveillance, epidemiologic, and end results database;Govindan;J. Clin. Oncol.,2006 5. Non-small cell lung cancer: Epidemiology, risk factors, treatment, and survivorship;Molina;Mayo Clin. Proc.,2008
|
|